enGene (NASDAQ:ENGN) Issues Earnings Results

Posted by on Sep 8th, 2026

enGene (NASDAQ:ENGN – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.47) earnings per share for the quarter, meeting the consensus estimate of ($0.47), FiscalAI reports.

enGene Price Performance

Shares of NASDAQ ENGN opened at $1.82 on Tuesday. enGene has a 1 year low of $1.40 and a 1 year high of $12.25. The firm’s 50-day moving average is $1.82 and its 200-day moving average is $4.11. The company has a current ratio of 12.57, a quick ratio of 12.57 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $121.92 million, a PE ratio of -0.84 and a beta of -0.28.

Hedge Funds Weigh In On enGene

Several large investors have recently bought and sold shares of the business. Cresset Asset Management LLC acquired a new stake in enGene during the 2nd quarter worth $36,000. Paloma Partners Management Co acquired a new position in shares of enGene in the 2nd quarter valued at $38,000. Raymond James Financial Inc. lifted its stake in shares of enGene by 383.6% in the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after purchasing an additional 7,932 shares during the period. Citadel Advisors LLC lifted its stake in shares of enGene by 153.3% in the 3rd quarter. Citadel Advisors LLC now owns 58,370 shares of the company’s stock valued at $399,000 after purchasing an additional 35,327 shares during the period. Finally, Millennium Management LLC boosted its position in shares of enGene by 57.3% in the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after purchasing an additional 7,472 shares during the last quarter. 64.16% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of enGene from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of enGene in a report on Wednesday, August 12th. Morgan Stanley cut shares of enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price objective for the company. in a research report on Thursday, June 18th. HC Wainwright reduced their price objective on enGene from $6.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, June 16th. Finally, UBS Group decreased their price objective on enGene from $9.00 to $2.00 and set a “neutral” rating on the stock in a research report on Thursday, May 14th. Four equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, enGene currently has a consensus rating of “Hold” and an average price target of $11.05.

Get Our Latest Analysis on enGene

About enGene

(Get Free Report)

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Further Reading

Earnings History for enGene (NASDAQ:ENGN)

Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.